C4 Therapeutics Inc is a clinical-stage biopharmaceutical company dedicated to delivering on the promise of targeted protein degradation science to create a new generation of medicines that transforms patient's lives. The Company is progressing targeted oncology programs through clinical studies and leveraging its TORPEDO platform to efficiently design and optimize small-molecule medicines to address difficult-to-treat diseases. The degrader medicines of the company are designed to harness the body's natural protein recycling system to rapidly degrade disease-causing proteins, offering the potential to overcome drug resistance, and drug undruggable targets and improve patient outcomes. Its pipeline is Cemsidomide, CFT8919, and other discovery products.
Last trade$2.56
Day change-$0.095 (-3.58%)
Day range$2.38 – $2.69
Volume1,860,733
Market cap$348M
OpenXNAS
Fundamentals
Key company ratios and reported financial statements.
Source: Massive.com
Key ratios
Valuation
Market capitalization
$347.99M
Price / earnings
—
Price / book
1.53×
Price / sales
10.78×
EV / sales
9.78×
EV / EBITDA
-3.14×
Profitability
Earnings per share
-$0.69
Return on assets
-27.45%
Return on equity
-39.92%
Dividend yield
0%
Liquidity and leverage
Debt / equity
0×
Current ratio
5.17×
Quick ratio
5.17×
Cash ratio
0.78×
Cash flow
Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$79.74M
Ratios use trailing-twelve-month financials and market data as of
Nov 16, 2026.
Financial statements
Income and cash flow amounts are for the period; balance sheets are point-in-time
snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are
displayed when available.
Income statement for CCCC, quarterly periods
Line item
Q3 FY2026 Sep 30, 2026
Q2 FY2026 Jun 30, 2026
Q1 FY2026 Mar 31, 2026
Q4 FY2025 Dec 31, 2025
Q3 FY2025 Sep 30, 2025
Q2 FY2025 Jun 30, 2025
Q1 FY2025 Mar 31, 2025
Q4 FY2024 Dec 31, 2024
Revenue
$8.47M
$6.64M
$6.15M
$11.02M
$11.23M
$6.46M
$7.24M
$5.18M
Cost of revenue
$0
$0
$0
$0
$0
$0
$0
$0
Gross profit
$8.47M
$6.64M
$6.15M
$11.02M
$11.23M
$6.46M
$7.24M
$5.18M
Selling, general and administrative
$8.26M
$8.59M
$9.33M
$9.18M
$8.92M
$8.77M
$9.33M
$10.37M
Research and development
$24.8M
$24.47M
$24.61M
$24.98M
$25.99M
$26.2M
$27.07M
$32.51M
Total operating expenses
$33.06M
$33.06M
$33.94M
$34.16M
$45.64M
$34.96M
$36.4M
$42.89M
Operating income
-$24.6M
-$26.42M
-$27.79M
-$23.15M
-$34.41M
-$28.5M
-$29.16M
-$37.71M
Interest expense
$0
$0
$0
$0
$0
$0
$0
$0
Income before taxes
-$21.84M
-$23.64M
-$25.13M
-$20.37M
-$32.17M
-$26.02M
-$26.32M
-$34.44M
Income taxes
$0
$0
$0
$121K
$0
$0
$0
$131K
Net income
-$21.84M
-$23.64M
-$25.13M
-$20.49M
-$32.17M
-$26.02M
-$26.32M
-$34.57M
Net income attributable to common shareholders
-$21.84M
-$23.64M
-$25.13M
-$20.49M
-$32.17M
-$26.02M
-$26.32M
-$34.57M
EBITDA
-$24.28M
-$26.13M
-$27.38M
-$22.72M
-$23.22M
-$27.89M
-$28.71M
-$37.23M
Basic earnings per share
-$0.16
-$0.18
-$0.20
-$0.17
-$0.44
-$0.37
-$0.37
-$0.49
Diluted earnings per share
-$0.16
-$0.18
-$0.20
-$0.17
-$0.44
-$0.37
-$0.37
-$0.49
Recent news
Company coverage with links to the original publishers.
MacroGenics (MGNX) and C4 Therapeutics (CCCC) are outperforming the broader Medical sector year-to-date. MGNX has returned 120.5% compared to a -0.4% average for Medical stocks, with analyst consensus estimates for full-year earnings up 50.6% over the past three months. CCCC has returned 49.2% with a 1.7% increase in consensus EPS estimates. Both stocks hold Zacks Rank #2 (Buy) ratings.
C4 Therapeutics presented biomarker data from its Phase 1 trial of cemsidomide combined with dexamethasone in relapsed/refractory multiple myeloma patients, demonstrating robust T-cell activation and immune cell function. The company also shared preliminary data from a Phase 1b trial combining cemsidomide with elranatamab, showing enhanced CD8+ T-cell expansion and prevention of T-cell exhaustion. The 75 µg dose level was declared safe, allowing advancement to dose escalation and expansion cohorts with full data expected in mid-2027.
C4 Therapeutics (CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation, announced its management will participate in three major healthcare conferences in May and June 2026, including TD Cowen's Oncology Innovation Summit, Jefferies Global Healthcare Conference, and Goldman Sachs Global Healthcare Conference. The company is progressing targeted oncology programs and leveraging its TORPEDO platform for drug development.
C4 Therapeutics (CCCC), a clinical-stage biopharmaceutical company focused on targeted protein degradation, announced that management will participate in a fireside chat at the Guggenheim Emerging Outlook: Biotech Summit 2026 on February 11, 2026 in New York. The company is progressing targeted oncology programs including cemsidomide Phase 2 MOMENTUM trial expected to initiate in Q1 2026 and a Phase 1b combination trial with elranatamab planned for Q2 2026.
C4 Therapeutics announced strategic milestones through 2028 for advancing cemsidomide, an investigational IKZF1/3 degrader for multiple myeloma. The company plans to initiate Phase 2 MOMENTUM trial in Q1 2026 and Phase 1b combination trial with elranatamab in Q2 2026, with a recommended Phase 2 dose of 100 µg. Phase 1 data showed 53% overall response rate at the highest dose. The company also outlined a new discovery strategy targeting inflammation and neurodegenerative diseases, with cash runway extending through end of 2028.
Dividends
Declared distributions and recorded event dates. Forecasts are not
shown.
Updated daily
No declared upcoming dividend found.
No prior dividend records found.
Stock splits
Historical share-structure events and their execution dates.